Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 226Lung Neoplasms 78Neoplasms 37Mesothelioma 23Mesothelioma, Malignant 21Neoplasm Metastasis 20Breast Neoplasms 18Adenocarcinoma of Lung 18Head and Neck Neoplasms 13Colorectal Neoplasms 13Ovarian Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Carcinoma 8Uterine Cervical Neoplasms 6Non-Squamous Non-Small Cell Lung Cancer 6Adenocarcinoma, Bronchiolo-Alveolar 6Adenocarcinoma 6Unspecified Adult Solid Tumor, Protocol Specific 5Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Meningeal Carcinomatosis 5Brain Neoplasms 5Urinary Bladder Neoplasms 4Small Cell Lung Carcinoma 4Recurrence 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Laryngeal Diseases 4Endometrial Neoplasms 4

Interventions

trametinib 1talimogene laherparepvec 1spartalizumab 1nazartinib 1canakinumab 1Therapeutics 1Telomerase 1Radiation, Ionizing 1Pemetrexed 1Paclitaxel 1Indocyanine Green 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Ductal × Pemetrexed × Clear all
NCT00106002 2009-06-01

Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer

Eli Lilly and Company

Phase 2 Completed
37 enrolled 9 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Carcinoma, Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡